Seriousness – no. (%) |
Seriousness –
no. (%) |
|
|
|
|
|
Serious cases |
454 (72) |
153 (58) |
301 (82) |
<0.001 |
|
Deaths |
30 (5) |
8 (3) |
22 (6) |
.058 |
Gender – no. (%) |
Gender – no. (%) |
|
|
|
|
|
Females
Males
Unknown
|
355 (56)
267 (42)
9 (1)
|
219 (83)
39 (15)
7 (3)
|
136 (37)
228 (62)
2 (1)
|
<0.001
|
Age – yr. |
Age – yr. |
|
|
|
|
|
Median (IQRa) |
59 (45 – 70) |
50.0 (36.8 – 65.0) |
61.0 (51.0 – 72.0) |
<0.001 |
Age group – no. (%) |
Age group – no.
(%) |
|
|
|
|
|
Newborn
Breastfed
Child
Adolescent
Adult
> 65 years
Unknown
|
4 (1)
2 (0)
8 (1)
3 (1)
395 (63)
198 (31)
21 (3)
|
4 (2)
1 (0)
5 (2)
2 (1)
180 (68)
55 (21)
18 (7)
|
0 (0)
1 (0)
3 (1)
1 (0)
215 (59)
143 (39)
3 (1)
|
|
Daily HCQ dose – no. (%) |
Daily HCQ
dose – no. (%) |
|
|
|
|
|
Low, < 400 mg /d
Medium, 400-600 mg/d
High, 800 mg/d
Unknown
|
126 (20)
209 (33)
37 (6)
259 (41)
|
111 (42)
47 (18)
0 (0)
107 (40)
|
15 (4)
162 (44)
37 (10)
152 (41)
|
<0.001
|
Total HCQ dose – mg |
Total HCQ dose –
mg |
|
|
|
|
|
Median (IQR) |
2,800 (1,600 - 5,900) |
21,600 (5,400 – 87,800) |
2,400 (1,600 – 3,100) |
<0.001 |
Total HCQ dose – no. (%) |
Total HCQ
dose – no. (%) |
|
|
|
|
|
Low (≤ 50.000 mg)
Medium (51.000-200.000 mg)
High (> 200.000 mg)
Unknown
|
271 (42.9)
14 (2.2)
16 (2.5)
330 (52.3)
|
63 (23.8)
14 (5.3)
16 (6.0)
172 (64.9)
|
208 (56.8)
0 (0)
0 (0)
158 (43.2)
|
<0.001
|
Length of treatment with HCQ – days, no. (%) |
Length of treatment with HCQ – days, no. (%) |
|
|
|
|
|
Median (IQR) |
7 (5 - 17) |
65 (18 - 365) |
6 (4 - 7) |
<0.001 |
|
Short (≤ 10 days)
Medium (11-90 days)
Long (> 90 days)
Unknown
|
283 (44.8)
73 (11.6)
61 (9.7)
214 (33.9)
|
20 (7.5)
51 (19.2)
59 (22.3)
135 (50.9)
|
263 (71.9)
22 (6.0)
2 (0.5)
79 (21.6)
|
<0.001
|
Indications – no. (%) |
Indications –
no. (%) |
|
|
|
|
|
Covid19
Arthropathy
Lupus erythematosus
Sjögren’s syndrome
Dermatomyositis
Connective tissue disorder
Lichen
Alopecia
Antiphospholipid syndrome
Collagen disorder
Polymyositis
Cutaneous sarcoidosis
Othersb
Unknown
|
366 (58)
90 (14)
84 (13)
9 (1)
6 (1)
5 (1)
5 (1)
5 (1)
3 (1)
2 (0)
2 (0)
2 (0)
10 (2)
42 (7)
|
0 (0)
90 (34)
84 (32)
9 (3)
6 (2)
5 (2)
5 (2)
5 (2)
3 (1)
2 (1)
2 (1)
2 (1)
10 (3)
42 (16)
|
366 (100)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
|
|
Total drugs - no. (%) |
Total drugs - no.
(%) |
|
|
|
|
|
Median (IQR)
1 drug (only HCQ)
2-10 drugs
> 10 drugs
|
3.0 (2 - 4)
157 (24.9)
456 (72.3)
18 (2.9)
|
1.0 (1 - 4)
136 (51.3)
125 (47.2)
4 (1.5)
|
4.0 (3 - 5)
21 (5.7)
331 (90.4)
14 (3.8)
|
<0.001
|
More frequent pharmacologic groups – no. (%) |
More frequent pharmacologic groups – no. (%) |
More frequent pharmacologic groups – no. (%) |
|
|
|
|
antibacterials
antivirals
corticosteroids
immunosuppressants (IL inhib.)
immunosuppressants
antithrombotics
analgesics
drugs for peptic ulcer
|
79 (44)
204 (32)
119 (19)
85 (13)
76 (12)
62 (10)
60 (10)
44 (7)
|
10 (4)
0 (0)
63 (24)
5 (2)
57 (22)
18 (7)
23 (9)
18 (7)
|
269 (73)
204 (32)
119 (19)
85 (13)
76 (12)
62 (10)
60 (10)
44 (7)
|
|